| Don Son, Md, Inc. | |
|
408 S Beach Blvd Ste 206 Anaheim CA 92804-1853 | |
| (714) 527-2240 | |
| (714) 527-2328 |
| Full Name | Don Son, Md, Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 408 S Beach Blvd Ste 206, Anaheim, California |
| Authorized Official Name and Position | Don Dongsoo Son (PRESIDENT) |
| Authorized Official Contact | 7145272240 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Don Son, Md, Inc. 408 S Beach Blvd Suite 204 Anaheim CA 92804-1878 Ph: (714) 527-2240 | Don Son, Md, Inc. 408 S Beach Blvd Ste 206 Anaheim CA 92804-1853 Ph: (714) 527-2240 |
| NPI Number | 1629332614 |
|---|---|
| Provider Enumeration Date | 06/25/2012 |
| Last Update Date | 02/11/2019 |
| Medicare PECOS PAC ID | 5092970384 |
|---|---|
| Medicare Enrollment ID | O20120712000367 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
What happens to the human retina at the cellular level when it's exposed to the hyperglycemic conditions of diabetes? No known imaging technique has been able to show such biochemical changes – until now.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629332614 | NPI | - | NPPES |
| 6977240 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | A121306 (California) | Primary |
| Provider Name | Don D Son |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558564898 PECOS PAC ID: 0749335461 Enrollment ID: I20120712000508 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
What happens to the human retina at the cellular level when it's exposed to the hyperglycemic conditions of diabetes? No known imaging technique has been able to show such biochemical changes – until now.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center.
› Verified 1 days ago
| Provider Name | Ji Hye Whang |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093358533 PECOS PAC ID: 0345602009 Enrollment ID: I20230811000687 |
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
What happens to the human retina at the cellular level when it's exposed to the hyperglycemic conditions of diabetes? No known imaging technique has been able to show such biochemical changes – until now.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center.
› Verified 1 days ago
News Archive
Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.
What happens to the human retina at the cellular level when it's exposed to the hyperglycemic conditions of diabetes? No known imaging technique has been able to show such biochemical changes – until now.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center.
› Verified 1 days ago
The Family Medicine Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1211 W. La Palma Avenue, Suite #404, Anaheim, CA 92801 Phone: 714-772-1030 Fax: 714-772-1758 | |
Anaheim Medical Group Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2571 W La Palma Ave, Anaheim, CA 92801 Phone: 714-827-9797 Fax: 714-827-5377 | |
Shirdi Medical Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1751 W Romneya Dr, Anaheim, CA 92801 Phone: 714-776-3180 Fax: 714-991-1932 | |
Rakesh Kumar Bhola ,m.d. Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1781 W Romneya Dr Ste C, Anaheim, CA 92801 Phone: 714-776-2700 | |
Anaheim Health Care Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1125 N Magnolia Ave, Anaheim, CA 92801 Phone: 714-484-1280 Fax: 714-484-1358 | |
Richard Dick M Yip Md A Medical Corp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 408 S Beach Blvd Ste 211, Anaheim, CA 92804 Phone: 714-527-6000 Fax: 714-527-2371 | |
Benevolence Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 303 N East St, Anaheim, CA 92805 Phone: 714-491-1771 |